Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide-Reference-Cited by-同舟云学术

Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide

Published:2016-06-23 Issue: Volume: Page:gfw242
ISSN:0931-0509
Container-title:Nephrology Dialysis Transplantation
language:en
Short-container-title:Nephrol. Dial. Transplant.

Author:

Covic Adrian C.,Floege Jürgen,Ketteler Markus,Sprague Stuart M.,Lisk Laura,Rakov Viatcheslav,Rastogi Anjay

Publisher

Oxford University Press (OUP)

Subject

Transplantation,Nephrology

Link

http://academic.oup.com/ndt/article-pdf/32/8/1330/19381364/gfw242.pdf

Reference27 articles.

1. Randomized Clinical Trial of the Iron-Based Phosphate Binder PA21 in Hemodialysis Patients

2. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients

3. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients

4. Sprague SM , Covic A , Floege J et al . Concomitant intravenous iron use drives changes in iron indices in a phase 3 study of PA21. Presented at: National Kidney Foundation, Las Vegas, NV, USA, 22‒26 April 2014

5. Combined High Serum Ferritin and Low Iron Saturation in Hemodialysis Patients: The Role of Inflammation

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sucroferric oxyhydroxide use in patients on haemodialysis – real-world experience from an Asian cohort;Proceedings of Singapore Healthcare;2023-09-25

2. Biochemical markers of iron status and iron accumulation in peritoneal dialysis patients treated with ferric citrate;Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis;2023-09-10

3. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure;Expert Opinion on Pharmacotherapy;2023-08-11

4. Efficacy and Safety of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in Chinese Dialysis Patients with Hyperphosphataemia: A Randomised, Open-Label, Multicentre, 12-Week Phase III Study;Nephron;2023-07-20

5. Long-term safety and efficacy of ferric citrate in phosphate-lowering and iron-repletion effects among patients with on hemodialysis: A multicenter, open-label, Phase IV trial;PLOS ONE;2022-03-03